PRESS RELEASE: Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program

Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Children's Dimetapp Cold & Chest Congestion

-- Dosage Cup Being Replaced, No Issue with Medicine --

Madison, N.J., October 29, 2007 – Wyeth Consumer Healthcare, a division of Wyeth (NYSE: WYE), today announced it has initiated a voluntary recall and replacement program for all U.S. retail outlets that sell several Robitussin® products and Children’s Dimetapp® Cold & Chest Congestion.  The program involves removal of existing products with a dosage cup that does not have a half-teaspoon mark, which is the recommended dose for children age two to under six.  This action is specific to the dosage cup and not related to the medication itself.  For children age two to under six, the Company is advising consumers not to use these medicines until the replacement products with the new cup are available.

The replacement products with the new dosage cup are expected to be available beginning in early November 2007.   Packaging for the replacement products will be marked to indicate that the new dosage cup is included.


The recall and replacement program for these products does not affect other Robitussin and Dimetapp cough and cold products.


Products Being Recalled & Replaced:
· Robitussin® Cough DM
· Robitussin® Cough & Cold CF
· Robitussin® Cough & Congestion
· Robitussin® Chest Congestion
· Robitussin® Head & Chest Congestion PE
· Robitussin® Cough Sugar Free DM
· Children’s Dimetapp® Cold & Chest Congestion

Important Instructions for Parents and Caregivers
We recommend that parents and caregivers of children age two to under six do the following:
· Do not use these medicines in children age two to under six because the dosage cup does not have a half-teaspoon mark, which is the dose on the label of these products for this age group. 
· Consult their healthcare professional concerning the most appropriate way to treat cough and cold symptoms for children age two to under six.
· Call 1-800-762-4675 for more information.

More information on these Robitussin products or Children’s Dimetapp Cold & Chest Congestion can be found at Dimetapp.com or Robitussin.com or by calling 800-762-4675.

About Wyeth Consumer Healthcare
Wyeth Consumer Healthcare, a division of Wyeth, is one of the world’s leaders in the development, manufacturing and marketing of non-prescription medicines, vitamins and nutritional products, including established brands such as Advil®, Centrum®, ChapStick®, Dimetapp® and Robitussin®.  Wyeth is one of the world’s largest research-driven pharmaceutical and health care products companies.  It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide.  The Company’s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products, including with respect to our pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; data generated on our products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption “Item 1A, Risk Factors.” The forward-looking statements in this press release are qualified by these risk factors.  We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.